 |
ESBATech, an Alcon Biomedical Research Unit
|
| |
ESBATech is a Zurich, Switzerland based Biomedical Research Unit of Alcon. The company has been acquired by Alcon, the world leader in Ophthalmology, on September 14, 2009. ESBATech lays the foundation for Alcon to move into biotechnology. Prior to the acquisition, ESBATech focused on advancing therapeutic antibody fragments in ophthalmology but also other fields. All rights outside of ophthalmology were spun-out to Delenex Therapeutics.
|
| |
|
|
Latest Company News
HUENENBERG and ZURICH, Switzerland – September 14, 2009
Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG
>> read complete press release
Zurich, Switzerland; March 24, 2009
Topical ESBA105 Demonstrates Efficacy in the Back of the Eye to Inhibit Neovascularization
>> read complete press release
Zurich, Switzerland; February 24, 2009
ESBATech’s Antibody Fragment ESBA105 Enters Phase IIa in Uveitis Study
>> read complete press release
Zurich, Switzerland; February 3, 2009
ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
>> read complete press release
Mountain View, California; January 26, 2009
Frost & Sullivan Recognizes ESBATech’s Innovation in Developing Antibody Fragments for Biologic Therapeutics
>> read complete press release
|
| |
|
|
|
|
ESBATech
Wagistrasse 21
CH-8952
Zurich-Schlieren
Switzerland
|
|
|
